Back to top

REGENXBIO Announces Publication of Preclinical Results Demonstrating Functional Benefits of ...

REGENXBIO Announces Publication of Preclinical Results Demonstrating Functional Benefits of Novel Microdystrophin Construct in RGX-202 Investigational Gene Therapy for Duchenne Muscular Dystrophy | RG

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

REGENXBIO Inc. (RGNX)